Published in Virology on February 05, 2005
Development of nonhuman adenoviruses as vaccine vectors. Vaccine (2005) 1.25
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology (2009) 1.02
Adenovirus receptors and their implications in gene delivery. Virus Res (2009) 0.98
Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res (2010) 0.93
Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochem Biophys Res Commun (2005) 0.91
Chapter two--Adenovirus strategies for tissue-specific targeting. Adv Cancer Res (2012) 0.90
Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses. Gene Ther (2010) 0.90
Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology (2009) 0.88
Usage of integrin and heparan sulfate as receptors for mouse adenovirus type 1. J Virol (2009) 0.88
Emerging cancer vaccines: the promise of genetic vectors. Cancers (Basel) (2011) 0.81
Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Hum Gene Ther (2014) 0.79
Persistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell lines. Virus Res (2011) 0.75
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet (2006) 2.10
Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther (2008) 1.84
Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets (2011) 1.65
Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther (2004) 1.49
Current strategies and future directions for eluding adenoviral vector immunity. Curr Gene Ther (2006) 1.42
Development of nonhuman adenoviruses as vaccine vectors. Vaccine (2005) 1.25
Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res (2006) 1.24
Comparative transduction efficiencies of human and nonhuman adenoviral vectors in human, murine, bovine, and porcine cells in culture. Biochem Biophys Res Commun (2005) 1.19
A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis (2008) 1.13
Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther (2011) 1.07
Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res (2004) 1.03
Porcine circovirus type 2 (PCV2) causes apoptosis in experimentally inoculated BALB/c mice. BMC Vet Res (2005) 1.02
Adenoviral vector-based strategies for cancer therapy. Curr Drug ther (2009) 1.02
Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology (2002) 1.02
Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology (2009) 1.02
Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Expert Opin Biol Ther (2010) 1.01
Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One (2012) 1.00
Adenovirus receptors and their implications in gene delivery. Virus Res (2009) 0.98
Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther (2005) 0.95
Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Rev Mol Med (2010) 0.93
Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS One (2013) 0.93
Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res (2010) 0.93
Bovine adenovirus type 3 internalization is independent of primary receptors of human adenovirus type 5 and porcine adenovirus type 3. Biochem Biophys Res Commun (2005) 0.91
Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology (2009) 0.88
Modulation of PKR activity in cells infected by bovine viral diarrhea virus. Virus Res (2005) 0.86
Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin (2010) 0.85
Sequence analysis of old and new strains of porcine circovirus associated with congenital tremors in pigs and their comparison with strains involved with postweaning multisystemic wasting syndrome. Can J Vet Res (2002) 0.83
EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model. J Gene Med (2012) 0.80
Adenoviral E2 IVa2 protein interacts with L4 33K protein and E2 DNA-binding protein. J Gen Virol (2013) 0.79
Sequential administration of bovine and human adenovirus vectors to overcome vector immunity in an immunocompetent mouse model of breast cancer. Virus Res (2011) 0.78
Adenoviral vector expressing murine β-defensin 2 enhances immunogenicity of an adenoviral vector based H5N1 influenza vaccine in aged mice. Virus Res (2013) 0.77
A 72-bp internal deletion in the left inverted terminal repeat of the bovine adenovirus type 3 genome does not affect virus replication. Intervirology (2002) 0.77
Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time. Virus Res (2013) 0.75
Persistence and the state of bovine and porcine adenoviral vector genomes in human and nonhuman cell lines. Virus Res (2011) 0.75
Corrigendum: KANK1 inhibits cell growth by inducing apoptosis through regulating CXXC5 in human malignant peripheral nerve sheath tumors. Sci Rep (2017) 0.75